ST10 is an oral ferric iron-based pharmaceutical that can be administered to patients with improved tolerability compared to currently marketed oral iron treatments, the company said. The trial
Prolensa is a once-daily topical nonsteroidal anti-inflammatory (NSAID) compound which is used to treat ocular inflammation and pain following cataract surgery.. The two Phase 3 controlled, double-masked, multi-center,
Nexavar is an oral anti-cancer therapy for liver cancer and for the treatment of patients with advanced kidney cancer As per the deal, Bayer will have the final
The collaboration agreement is valued at €2.8m. As per the deal, BioFocus will provide expanded medicinal chemistry resource, biology services, and an option to perform ADME services for
The Phase III randomized, double-blind, placebo-controlled, parallel-design clinical study, assessed the safety and efficacy of Cialis 2.5 or 5 mg for once daily use in 606 sexually active
According to the deal, a new company Tasly-SemBioSys Pharmaceuticals will be set up in Tianjin, China, pharmabiz.com reported. The new project intends to develop and commercialize many products
DRP tested Skinvisible’s scientific data and validated the claims which said DermSafe is alcohol-free, offers protection from harmful bacteria, resists wash-off besides providing a moisture barrier for the
The order includes purchase of PrioClear, a prion capture resin incorporated into Octapharma’s manufacturing process for its solvent/detergent treated plasma product, Octaplas LG. The resumption of PrioClear supply
The vaccine, ID93/GLA-SE contains fusion protein of four antigens and a synthetic adjuvant formulation, which together enable T-cells to induce effective immunity and protect against TB ID93/GLA-SE will
The company inked a deal with Institute of Pharmacology and Toxicology of the Academy of Military Medical Sciences in China to complete final toxicology tests for AGX-1009, a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.